In the fast-evolving world of pharmaceutical manufacturing, the operation of evaporation is far more than simple solvent removal. It is a mission-critical, scientifically engineered transformation that directly determines product quality, therapeutic potency, and regulatory success. Achieving precise concentration through controlled evaporation is a cornerstone of product stability, bioavailability, shelf life, and successful downstream processing.

GLP-1 drugs like semaglutide and liraglutide are revolutionizing diabetes and obesity care by enhancing glucose control and driving weight loss. Their complex manufacturing spanning peptide synthesis, formulation, sterile injectables, and cold-chain logistics poses challenges but also opportunities. With global demand soaring and annual sales projected to exceed $100 billion by 2030, supply chain bottlenecks and device shortages remain critical barriers. As patents for blockb